从宫颈癌疫苗佳达修和卉妍康看跨国公司的专利运营

Research on the patent operation of transnational corporations based on vaccines for cervical cancer Gardasil and Cervarix

佳达修和卉妍康已销售近10年,期间再无其他宫颈癌疫苗产品进入全球市场。本文对默克公司和GSK从众多抗肿瘤疫苗研发公司中脱颖而出背后的专利运营策略进行了深度剖析,提出了有效构建专利组合的层次和方法,并且基于中小型医药企业常面对的已经形成产业专利壁垒的形势,针对如何开发专利资产来支撑企业竞争力提升的策略模式提出了相关建议。

Gardasil and Cervarix have been sold for almost 10 years,none of other vaccines for cervical cancer sold on the global market during the period. This paper investigates the patent operation strategy and tactics used by Merck and GSK,and gives some advice on how to design the firm＇s patent portfolio. Moreover,as for small and medium medical enterprises,this paper also gives some suggestions for the strategic countermeasures of dealing with patent barriers to exploit patent asset to support enterprises competitiveness promotion.